The projected growth in Linzess sales and total revenue guidance suggests a positive outlook for Ironwood Pharmaceuticals, which may support the stock price. However, the large one-time charge from the VectivBio acquisition could be a concern for investors, potentially offsetting the positive sales growth impact in the short term. The net effect might be neutral as the market absorbs both the growth prospects and the one-time financial hit.